Tyr505
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr505  -  Lck (mouse)

Site Information
FTATEGQyQPQP___   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447823
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 35 , 36 , 39 ) , electrophoretic mobility shift ( 35 ) , flow cytometry ( 21 , 23 , 30 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 16 , 17 , 18 , 19 , 24 , 25 , 26 , 27 , 28 , 29 , 31 ) , mutation of modification site ( 2 , 32 , 33 , 34 , 36 , 38 , 39 ) , phospho-antibody ( 1 , 2 , 3 , 13 , 15 , 20 , 21 , 22 , 23 , 30 , 33 , 34 , 36 ) , phosphoamino acid analysis ( 35 ) , phosphopeptide mapping ( 36 , 39 ) , western blotting ( 1 , 2 , 3 , 13 , 15 , 20 , 22 , 23 , 33 , 34 , 38 )
Disease tissue studied:
breast cancer ( 33 ) , leukemia ( 2 ) , T cell leukemia ( 2 ) , lymphoma ( 23 , 31 ) , T cell lymphoma ( 23 )
Relevant cell line - cell type - tissue:
32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 16 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 36 ) , 3T3 (fibroblast) ( 39 ) , AB.1 (T lymphocyte) ( 13 ) , B lymphocyte ( 6 , 7 ) , BaF3 ('B lymphocyte, precursor') ( 24 ) , BI-141 (T lymphocyte) ( 38 ) , brain ( 19 ) , BW5147 (T lymphocyte) [CD45 (mouse)] ( 23 ) , COS (fibroblast) ( 32 ) , HEK293T (epithelial) ( 3 ) , Jurkat (T lymphocyte) ( 2 , 35 ) , LSTRA (T lymphocyte) ( 35 ) , lymphocyte ( 1 , 20 ) , MCF-7 (breast cell) ( 33 ) , MDA-MB-231 (breast cell) ( 33 ) , Sor4 ( 26 , 28 ) , Sor577 ( 25 ) , SorA ( 27 , 29 ) , spleen ( 18 ) , T lymphocyte-blood ( 21 , 30 ) , T lymphocyte-lymph node ( 14 , 22 ) , T lymphocyte-thymus ( 34 ) , thymocyte ( 15 ) , thymus ( 17 )

Upstream Regulation
Regulatory protein:
CD4 (mouse) ( 23 ) , CD45 (mouse) ( 23 )
Putative in vivo kinases:
CSK (mouse) ( 37 )
Kinases, in vitro:
Lck (mouse) ( 35 )
Putative upstream phosphatases:
CD45 (mouse) ( 15 , 21 )
Phosphatases, in vitro:
CD45 (mouse) ( 37 )
Treatments:
anti-CD3 ( 30 ) , cell_adhesion ( 20 ) , H2O2 ( 13 ) , hypoxia/reoxygenation ( 33 ) , ionomycin ( 13 ) , miR-181a ( 22 ) , PAO ( 36 ) , thapsigargin ( 13 ) , vanadate ( 23 , 37 )

Downstream Regulation
Effects of modification on Lck:
enzymatic activity, inhibited ( 21 , 32 , 37 ) , intracellular localization ( 30 ) , protein stabilization ( 32 )
Effects of modification on biological processes:
apoptosis, altered ( 34 ) , cell cycle regulation ( 34 )

References 

1

Moogk D, et al. (2016) Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. J Immunol 197, 644-54
27271569   Curated Info

2

Dobbins J, et al. (2016) Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling. Sci Signal 9, ra75
27460989   Curated Info

3

Rangachari M, et al. (2012) Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat Med 18, 1394-400
22863785   Curated Info

4

Ren H (2011) CST Curation Set: 12902; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Ren H (2011) CST Curation Set: 12903; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Ren H (2011) CST Curation Set: 12893; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Ren H (2011) CST Curation Set: 12894; Year: 2011; Biosample/Treatment: primary cells, B lymphocyte/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Ren H (2011) CST Curation Set: 12895; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Ren H (2011) CST Curation Set: 12896; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Ren H (2011) CST Curation Set: 12897; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Ren H (2011) CST Curation Set: 12898; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Ren H (2011) CST Curation Set: 12900; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Lysechko TL, Cheung SM, Ostergaard HL (2010) Regulation of the tyrosine kinase Pyk2 by calcium is through production of reactive oxygen species in cytotoxic T lymphocytes. J Biol Chem 285, 31174-84
20688918   Curated Info

14

Iwai LK, Benoist C, Mathis D, White FM (2010) Quantitative phosphoproteomic analysis of T cell receptor signaling in diabetes prone and resistant mice. J Proteome Res 9, 3135-45
20438120   Curated Info

15

Zikherman J, et al. (2010) CD45-Csk phosphatase-kinase titration uncouples basal and inducible T cell receptor signaling during thymic development. Immunity 32, 342-54
20346773   Curated Info

16

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

17

Guo A (2009) CST Curation Set: 7710; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Guo A (2009) CST Curation Set: 7708; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Zhou J (2009) CST Curation Set: 7383; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

20

Monu N, Frey AB (2007) Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer Res 67, 11447-54
18056473   Curated Info

21

McNeill L, et al. (2007) The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 27, 425-37
17719247   Curated Info

22

Li QJ, et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129, 147-61
17382377   Curated Info

23

Falahati R, Leitenberg D (2007) Changes in the role of the CD45 protein tyrosine phosphatase in regulating Lck tyrosine phosphorylation during thymic development. J Immunol 178, 2056-64
17277109   Curated Info

24

Gu T (2005) CST Curation Set: 699; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Boccalatte F (2005) CST Curation Set: 635; Year: 2005; Biosample/Treatment: cell line, Sor577/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Boccalatte F (2005) CST Curation Set: 636; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

27

Boccalatte F (2005) CST Curation Set: 637; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Boccalatte F (2005) CST Curation Set: 566; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Boccalatte F (2005) CST Curation Set: 567; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Koneru M, et al. (2005) Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 174, 1830-40
15699109   Curated Info

31

Boccalatte F (2004) CST Curation Set: 500; Year: 2004; Biosample/Treatment: cell line, Tg 543/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Giannini A, Bijlmakers MJ (2004) Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol Cell Biol 24, 5667-76
15199125   Curated Info

33

Mahabeleshwar GH, Das R, Kundu GC (2004) Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem 279, 9733-42
14699120   Curated Info

34

Zhao R, Yang FT, Alexander DR (2004) An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation. Cancer Cell 5, 37-49
14749125   Curated Info

35

Kesavan KP, et al. (2002) Characterization of the in vivo sites of serine phosphorylation on Lck identifying serine 59 as a site of mitotic phosphorylation. J Biol Chem 277, 14666-73
11847223   Curated Info

36

Weil R, Veillette A (1994) Intramolecular and extramolecular mechanisms repress the catalytic function of p56lck in resting T-lymphocytes. J Biol Chem 269, 22830-8
7521333   Curated Info

37

Gervais FG, et al. (1993) The SH2 domain is required for stable phosphorylation of p56lck at tyrosine 505, the negative regulatory site. Mol Cell Biol 13, 7112-21
8413300   Curated Info

38

Chow LM, Fournel M, Davidson D, Veillette A (1993) Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature 365, 156-60
8371758   Curated Info

39

Veillette A, Fournel M (1990) The CD4 associated tyrosine protein kinase p56lck is positively regulated through its site of autophosphorylation. Oncogene 5, 1455-62
2250907   Curated Info